NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I'm not certain Merck's trial was very similar to NWBO's DCVAX trials.

Methods. Subjects with metastatic melanoma were vaccinated with mature DCs transfected with RNAs encoding melanoma antigens MART1, MAGE-3, gp100, and tyrosinase. These DCs were derived from monocytes that were untransfected (Arm A; n = 4), transfected with control siRNA (Arm B; n = 3), or transfected with siRNAs targeting the 3 inducible iP subunits (Arm C; n = 5).

--J Clin Invest. 2013 July 1; 123(7): 3135–3145.
Published online 2013 June 24. doi: 10.1172/JCI67544

[Emphasis added]

However, what I would say is that their use of dendritic cells in this study plus the pretrial clinical experiment liken back to where NWBO was in 2002 with their DCVAX technology.